34784980|t|Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
34784980|a|BACKGROUND: Parkinson's disease (PD) is a prevalent neurodegenerative disorder, displaying not only well-known motor deficits but also gastrointestinal dysfunctions. Consistently, it has been increasingly evident that gut microbiota affects the communication between the gut and the brain in PD pathogenesis, known as the microbiota-gut-brain axis. As an approach to re-establishing a normal microbiota community, fecal microbiota transplantation (FMT) has exerted beneficial effects on PD in recent studies. Here, in this study, we established a chronic rotenone-induced PD mouse model to evaluate the protective effects of FMT treatment on PD and to explore the underlying mechanisms, which also proves the involvement of gut microbiota dysbiosis in PD pathogenesis via the microbiota-gut-brain axis. RESULTS: We demonstrated that gut microbiota dysbiosis induced by rotenone administration caused gastrointestinal function impairment and poor behavioral performances in the PD mice. Moreover, 16S RNA sequencing identified the increase of bacterial genera Akkermansia and Desulfovibrio in fecal samples of rotenone-induced mice. By contrast, FMT treatment remarkably restored the gut microbial community, thus ameliorating the gastrointestinal dysfunctions and the motor deficits of the PD mice. Further experiments revealed that FMT administration alleviated intestinal inflammation and barrier destruction, thus reducing the levels of systemic inflammation. Subsequently, FMT treatment attenuated blood-brain barrier (BBB) impairment and suppressed neuroinflammation in the substantia nigra (SN), which further decreased the damage of dopaminergic neurons. Additional mechanistic investigation discovered that FMT treatment reduced lipopolysaccharide (LPS) levels in the colon, the serum, and the SN, thereafter suppressing the TLR4/MyD88/NF-kappaB signaling pathway and its downstream pro-inflammatory products both in the SN and the colon. CONCLUSIONS: Our current study demonstrates that FMT treatment can correct the gut microbiota dysbiosis and ameliorate the rotenone-induced PD mouse model, in which suppression of the inflammation mediated by the LPS-TLR4 signaling pathway both in the gut and the brain possibly plays a significant role. Further, we prove that rotenone-induced microbiota dysbiosis is involved in the genesis of PD via the microbiota-gut-brain axis. Video abstract.
34784980	42	50	rotenone	Chemical	MESH:D012402
34784980	59	78	Parkinson's disease	Disease	MESH:D010300
34784980	79	83	mice	Species	10090
34784980	100	112	inflammation	Disease	MESH:D007249
34784980	129	147	lipopolysaccharide	Chemical	MESH:D008070
34784980	148	152	TLR4	Gene	21898
34784980	222	241	Parkinson's disease	Disease	MESH:D010300
34784980	243	245	PD	Disease	MESH:D010300
34784980	262	288	neurodegenerative disorder	Disease	MESH:D019636
34784980	321	335	motor deficits	Disease	MESH:D009461
34784980	345	374	gastrointestinal dysfunctions	Disease	MESH:D005767
34784980	502	504	PD	Disease	MESH:D010300
34784980	697	699	PD	Disease	MESH:D010300
34784980	765	773	rotenone	Chemical	MESH:D012402
34784980	782	784	PD	Disease	MESH:D010300
34784980	785	790	mouse	Species	10090
34784980	852	854	PD	Disease	MESH:D010300
34784980	938	958	microbiota dysbiosis	Disease	MESH:D064806
34784980	962	964	PD	Disease	MESH:D010300
34784980	1047	1067	microbiota dysbiosis	Disease	MESH:D064806
34784980	1079	1087	rotenone	Chemical	MESH:D012402
34784980	1110	1146	gastrointestinal function impairment	Disease	MESH:D005767
34784980	1187	1189	PD	Disease	MESH:D010300
34784980	1190	1194	mice	Species	10090
34784980	1269	1280	Akkermansia	Species	239934
34784980	1285	1298	Desulfovibrio	Species	872
34784980	1319	1327	rotenone	Chemical	MESH:D012402
34784980	1336	1340	mice	Species	10090
34784980	1440	1469	gastrointestinal dysfunctions	Disease	MESH:D005767
34784980	1478	1492	motor deficits	Disease	MESH:D009461
34784980	1500	1502	PD	Disease	MESH:D010300
34784980	1503	1507	mice	Species	10090
34784980	1584	1596	inflammation	Disease	MESH:D007249
34784980	1659	1671	inflammation	Disease	MESH:D007249
34784980	1764	1781	neuroinflammation	Disease	MESH:D000090862
34784980	1850	1870	dopaminergic neurons	Disease	MESH:D009410
34784980	1947	1965	lipopolysaccharide	Chemical	MESH:D008070
34784980	1967	1970	LPS	Chemical	MESH:D008070
34784980	2043	2047	TLR4	Gene	21898
34784980	2048	2053	MyD88	Gene	17874
34784980	2054	2063	NF-kappaB	Gene	18033
34784980	2105	2117	inflammatory	Disease	MESH:D007249
34784980	2240	2260	microbiota dysbiosis	Disease	MESH:D064806
34784980	2280	2288	rotenone	Chemical	MESH:D012402
34784980	2297	2299	PD	Disease	MESH:D010300
34784980	2300	2305	mouse	Species	10090
34784980	2341	2353	inflammation	Disease	MESH:D007249
34784980	2370	2373	LPS	Chemical	MESH:D008070
34784980	2374	2378	TLR4	Gene	21898
34784980	2485	2493	rotenone	Chemical	MESH:D012402
34784980	2502	2522	microbiota dysbiosis	Disease	MESH:D064806
34784980	2553	2555	PD	Disease	MESH:D010300
34784980	Positive_Correlation	MESH:D012402	MESH:D010300
34784980	Positive_Correlation	MESH:D012402	MESH:D064806
34784980	Association	MESH:D012402	MESH:D007249
34784980	Association	MESH:D007249	21898
34784980	Positive_Correlation	MESH:D008070	MESH:D007249
34784980	Positive_Correlation	MESH:D012402	MESH:D005767
34784980	Association	MESH:D008070	21898
34784980	Association	MESH:D008070	MESH:D064806
34784980	Association	MESH:D012402	21898

